2012 and in press

Bosch OG, Quednow BB, Seifritz E, Wetter TC. Reconsidering GHB: orphan drug or new model antidepressant? J Psychopharmacol. 2012 May;26(5):618-28.

Bosch OG & Höfer FXE (2012): Annäherungen und Oszillationen – Aspekte des Rausches bei Benn und Jünger. In: Passie T (Hrsg.): Ekstasen: Kontexte – Formen – Wirkungen. Bibliotheca Academica. Ergon Verlag, Würzburg: 345-359.

Bosch OG, Seifritz E and Wetter TC (2012): Stress-related depression: neuroendocrine, genetic, and therapeutical aspects. World Journal of Biological Psychiatry 13 (8):556-568.

Bosch OG & Wetter TC (2012): Stress & Depression. In: Böker H und Seifritz E (Hrsg.): Psychotherapie und Neurowissenschaften. Verlag Hans Huber, Bern: 352-387.

Hulka LM, Wagner M, Preller KH, Jenni D, Quednow BB. Blue-yellow colour vision impairment and cognitive deficits in occasional and dependent stimulant users. Int J Neuropsychopharmacol. published online 2012 Jun 18:1-13.

Lennertz L, Quednow BB, Schuhmacher A, Petrovsky N, Frommann I, Schulze-Rauschenbach S, Landsberg MW, Steinbrecher A, Höfels S, Pukrop R, Klosterkötter J, Franke PE, Wölwer W, Gaebel W, Häfner H, Maier W, Wagner M, Mössner R. The functional coding variant Asn107Ile of the neuropeptide S receptor gene (NPSR1) is associated with schizophrenia and modulates verbal memory and the acoustic startle response. Int J Neuropsychopharmacol. 2012 Oct;15(9):1205-15. Epub 2011 Nov 14.

Mössner R, Schuhmacher A, Wagner M, Lennertz L, Steinbrecher A, Quednow BB, Rujescu D, Rietschel M, Maier W. The schizophrenia risk gene ZNF804A influences the antipsychotic response of positive schizophrenia symptoms. Eur Arch Psychiatry Clin Neurosci. 2012 Apr;262(3):193-7.

Petrovsky N, Ettinger U, Quednow BB, Walter H, Schnell K, Kessler H, Mössner R, Maier W, Wagner M. Nicotine differentially modulates antisaccade performance in healthy male non-smoking volunteers stratified for low and high accuracy. Psychopharmacology (Berl). 2012 May;221(1):27-38.

Preller KH, Ingold N, Hulka LM, Vonmoos M, Jenni D, Baumgartner MR, Vollenweider FX, Quednow BB. Increased Sensorimotor Gating in Recreational and Dependent Cocaine Users Is Modulated by Craving and Attention-Deficit/Hyperactivity Disorder Symptoms. Biol. Psychiatry 2012 Sep 4 (in press).

Preller KH, Wagner M, Sulzbach C, Hoenig K, Neubauer J, Franke PE, Petrovsky N, Frommann I, Rehme AK, Quednow BB. Sustained incentive value of heroin-related cues in short- and long-term abstinent heroin users. Eur Neuropsychopharmacol. 2012 Dec 6.

Quednow BB, Brinkmeyer J, Mobascher A, Nothnagel M, Musso F, Gründer G, Savary N, Petrovsky N, Frommann I, Lennertz L, Spreckelmeyer KN, Wienker TF, Dahmen N, Thuerauf N, Clepce M, Kiefer F, Majic T, Mössner R, Maier W, Gallinat J, Diaz-Lacava A, Toliat MR, Thiele H, Nürnberg P, Wagner M, Winterer G. Schizophrenia risk polymorphisms in the TCF4 gene interact with smoking in the modulation of auditory sensory gating. Proc Natl Acad Sci U S A. 2012 Apr 17;109(16):6271-6.

Quednow BB, Kometer M, Geyer MA, Vollenweider FX. Psilocybin-induced deficits in automatic and controlled inhibition are attenuated by ketanserin in healthy human volunteers. Neuropsychopharmacology. 2012 Feb;37(3):630-40.

Quednow BB, Treyer V, Hasler F, Dörig N, Wyss MT, Burger C, Rentsch KM, Westera G, Schubiger PA, Buck A, Vollenweider FX. Assessment of serotonin release capacity in the human brain using dexfenfluramine challenge and [18F]altanserin positron emission tomography. Neuroimage. 2012 Feb 15;59(4):3922-32.

Schuhmacher A, Becker T, Rujescu D, Quednow BB, Lennertz L, Wagner M, Benninghoff J, Rietschel M, Häfner H, Franke P, Wölwer W, Gaebel W, Maier W, Mössner R. Investigation of tryptophan hydroxylase 2 (TPH2) in schizophrenia and in the response to antipsychotics. J Psychiatr Res. 2012 Aug;46(8):1073-80.

Teltzrow R & Bosch OG (2012): Ecstatic anaesthesia: ketamine and GHB between self-experimentation and medical use. In: Wouters Marije, Fountain J, Korf D: The meaning of high. Variations according to drug, set, setting and time. Pabst Science Publishers, Lengerich: 80-97.

Völter C, Riedel M, Wöstmann N, Aichert DS, Lobo S, Costa A, Schmechtig A, Collier DA, Hartmann AM, Giegling I, Möller HJ, Quednow BB, Rujescu D, Kumari V, Ettinger U. Sensorimotor gating and D2 receptor signalling: evidence from a molecular genetic approach. Int J Neuropsychopharmacol. 2012 Nov;15(10):1427-40.

2011

Bosch OG & Höfer FXE (2011): La Gaya Dementia – Nietzsche als Patient. Weimar-Jena: Die große Stadt. Das kulturhistorische Archiv 4 (1): 6-17.

Lennertz, L; Quednow, BB; Benninghoff, J; Wagner, M; Maier, W; Mössner, R (2011). Impact of TCF4 on the genetics of schizophrenia. Eur Arch Psychiatry Clin Neurosci, 261 Suppl, 2:161-165.

Quednow, BB; Ettinger, U; Mössner, R; Rujescu, D; Giegling, I; Collier, DA; Schmechtig, A; Kühn, KU; Möller, HJ; Maier, W; Wagner, M; Kumari, V (2011). The schizophrenia risk allele C of the TCF4 rs9960767 polymorphism disrupts sensorimotor gating in schizophrenia and healthy volunteers. J Neurosci, 31:6684-6691.

Quednow BB (2011). Muß nur die Chemie stimmen? Verbesserung der Gehirnleistung durch Drogen und Neuropsychopharmaka. In: Vogelsang F (Ed.): Sollen wir den Menschen verbessern? Versprechungen und Perspektiven des Neuroenhancements. Reihe: Begegnungen. Evangelische Akademie im Rheinland: Bonn.

2010

Mössner, R; Schuhmacher, A; Wagner, M; Quednow, B B; Frommann, I; Kühn, K U; Schwab, S G; Rietschel, M; Falkai, P; Wölwer, W; Ruhrmann, S; Bechdolf, A; Gaebel, W; Klosterkötter, J; Maier, W (2010). DAOA/G72 predicts the progression of prodromal syndromes to first episode psychosis. European Archives of Psychiatry and Clinical Neuroscience, 260:209-215.

Petrovsky, N; Quednow, B B; Schmechtig, A; Mössner, R; Ettinger, U; Collier, D A; Kühn, K U; Maier, W; Wagner, M; Kumari, V (2010). Sensorimotor gating is associated with CHRNA3 polymorphisms in schizophrenia and healthy volunteers. Neuropsychopharmacology, 35:1429-1439.

Quednow, BB (2010). Tyrannische Neurobiologie und unterdrückte Kultur des psychotropen Erlebens. Zeitschrift für Kulturwissenschaften, 2:79-84.

Quednow, BB (2010). Neurophysiologie des Neuroenhancements: Möglichkeiten und Grenzen. SuchtMagazin, 2:19-26.

Quednow, BB (2010). Ethics of neuroenhancement: a phantom debate. BioSocieties 5:153-156.

Quednow, B B; Wagner, M; Mössner, R; Maier, W; Kühn, K U (2010). Sensorimotor gating of schizophrenia patients depends on catechol O-methyltransferase Val158Met polymorphism. Schizophrenia Bulletin, 36: 341-346.

Rehme, A K; Frommann, I; Peters, S; Block, V; Bludau, J; Quednow, B B; Maier, W; Schütz, C; Wagner, M (2010). Appetitive drug cue effects in former and active smokers. Addiction, 104:1757-1764. .

Roder, V; Hulka, L; Medalia, A (2010). Combined treatment approaches: overview and empirical results. In: Roder, V; Medalia, A. Understanding and treating neurocognition and social cognition in schizophrenia patients. Basel, Switzerland: Karger.

2009

Hasler, F; Kuznetsova, O F; Krasikova, R N; Cservenyak, T; Quednow, B B; Vollenweider, F X; Schubiger, P A; Westera, G (2009). Optimized radiosynthesis and metabolite analysis of [18F]altanserin and its biomedical application. Applied Radiation and Isotopes, 67:598-601.

Mössner, R; Schuhmacher, A; Kühn, K U; Cvetanovska, G; Rujescu, D; Zill, P; Quednow, B B; Rietschel, M; Wölwer, W; Gaebel, W; Wagner, W; Maier, W (2009). A functional serotonin-1A receptor variant influences treatment response to atypical antipsychotics in schizophrenia. Pharmacogenetics and Genomics, 19:91-94.

Quednow, B B; Geyer, M A; Halberstadt, A L (2009). Serotonin and schizophrenia. In: Müller, C P; Jacobs, B. Handbook of the Behavioural Neurobiology of Serotonin. London, UK: Academic Press, p. 585-620.

Quednow, B B; Schmechtig, A; Ettinger, U; Petrovsky, N; Collier, D A; Vollenweider, F X; Wagner, M; Kumari, V (2009). Sensorimotor gating depends on polymorphisms of the 5-HT2A receptor and COMT, but not on neuregulin-1 Arg38Gln genotype: a replication study. Biological Psychiatry, 66:614-620.

Schuhmacher, A; Mössner, R; Quednow, B B; Kühn, K U; Wagner, M; Cvetanovska, G; Rujescu, D; Zill, P; Möller, H J; Rietschel, M; Franke, P; Wölwer, W; Gaebel, W; Maier, W (2009). Influence of 5-HT3 receptor subunit genes 5-HT3A, B, C, D, E on treatment response to antipsychotics in schizophrenia. Pharmacogenetics and Genomics, 19: 843-851.

2008

Csomor, P A; Yee, B K; Vollenweider, F X; Feldon, J; Nicolet, T; Quednow, B B (2008). On the influence of baseline startle reactivity on the indexation of prepulse inhibition. Behavioral Neuroscience, 122:885-900.

Maier, W; Mössner, R; Quednow, B B; Wagner, M; Hurlemann, R (2008). From genes to psychosis and back: the role of the 5-HT2A receptor and prepulse inhibition in schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 258 (SUPPL. 5): 40-43.

Pfaff, M; Quednow, B B; Brüne, M; Juckel, G (2008). Schizophrenie und Religiosität. Eine Vergleichsstudie zur Zeit der innerdeutschen Teilung. Psychiatrische Praxis, 35:240-246.

Quednow, B B (2008). Defizite der sensomotorischen Filterleistung bei psychiatrischen Erkrankungen. Zeitschrift für Neuropsychologie, 19:139-163.

Quednow, B B; Csomor, P A; Chmiel, J; Beck, T; Vollenweider, F X (2008). Sensorimotor gating and attentional set-shifting are improved by the μ-opioid receptor agonist morphine in healthy human volunteers. The International Journal of Neuropsychopharmacology, 11:655-669.

Quednow, B B; Frommann, I; Berning, J; Maier, W; Kühn, K U; Wagner, M (2008). Sensorimotor gating and habituation of the startle response in the prodrome of schizophrenia. Biological Psychiatry, 64:766-773.

Quednow, B B; Kühn, K U; Maier, W; Mössner, R; Schwab, S G; Wagner, M (2008). Sensorimotor gating of schizophrenia patients is influenced by 5-HT2A receptor polymorphisms. Biological Psychiatry, 64: 434-437.

Westheide, J; Quednow, B B; Kuhn, K U; Hoppe, C; Cooper-Makorn, D; Hawellek, B; Eichler, P; Maier, W; Wagner, M (2008). Executive performance of depressed suicide attempters: The role of suicidal ideation. European Archives of Psychiatry and Clinical Neuroscience, 258:414-421.

2007

Quednow, B B; Kühn, K U; Hoppe, C; Westheide, J; Maier, W; Daum, I; Wagner, M (2007). Elevated impulsivity and impaired decision-making cognition in heavy users of MDMA (“Ecstasy”). Psychopharmacology, 189:517-530.

Vollenweider, F X; Csomor, P A; Knappe, B; Geyer, M A; Quednow, B B (2007). The effects of the preferential 5-HT2A agonist psilocybin on prepulse inhibition of startle in healthy human volunteers depend on interstimulus interval. Neuropsychopharmacology, 32:1876-1887.

Westheide, J; Wagner, M; Quednow, B B; Hoppe, C; Mahkohrn, D; Strater, B; Maier, W; Kuhn, K U (2007). Neuropsychological performance in partly remitted unipolar depressive patients: focus on executive functioning. European Archives of Psychiatry and Clinical Neuroscience, 257:389-395.

2006

Csomor, P A; Yee, B K; Stadler, R; Quednow, B B; Feldon, J; Vollenweider, F X (2006). The monotonic dependency of prepulse inhibition of the acoustic startle reflex on the intensity of the startle-eliciting stimulus. Behavioural Brain Research, 174:143-150.

Quednow, B B; Jessen, F; Kühn, K U; Maier, W; Daum, I; Wagner, M (2006). Memory deficits in abstinent MDMA (“Ecstasy”) users: neuropsychological evidence of frontal dysfunction. Journal of Psychopharmacology, 20:373-384.

Quednow, B B; Kühn, K U; Beckmann, K; Westheide, J; Maier, W; Wagner, M (2006). Attenuation of the prepulse inhibition of the acoustic startle response within and between sessions. Biological Psychology, 71: 256-263.

Quednow, B B; Kühn, K U; Westheide, J; Beckmann, K; Bliesener, N; Maier, W; Wagner, M (2006). Sensorimotor gating and habituation of the startle response in schizophrenic patients randomly treated with amisulpride or olanzapine. Biological Psychiatry, 59:536-545.

Quednow, B B; Westheide, J; Kühn, K U; Werner, P; Maier, W; Hawellek, B; Wagner, M (2006). Normal prepulse inhibition and habituation of acoustic startle response in suicidal depressive patients without psychotic symptoms. Journal of Affective Disorders, 92:299-303.

2005

Hoenig, K; Hochrein, A; Quednow, B B; Maier, W; Wagner, M (2005). Impaired prepulse inhibition of the acoustic startle response in obsessive-compulsive disorder. Biological Psychiatry, 57:1153-1158.

Kühn, K U; Quednow, B B; Riedel, M; Krampe, O; Maier, W (2005). Sicherheit und Effektivität von Citalopram in der Behandlung depressiver Erkrankungen. Psychopharmakotherapie, 12:83-90.

Quednow, B B (2005). Folgen des Ecstasy-Konsums, Neurobiologische Grundlagen kognitiver Leistungsdefizite bei MDMA-Konsumenten. Frankfurt am Main, Germany: Peter Lang.

Wagner, M; Quednow, B B; Westheide, J; Schlaepfer, T; Maier, W; Kühn, K U (2005). Cognitive improvement in schizophrenic patients by modern antipsychotics does not require a serotonergic mechanism: Randomized controlled trial of olanzapine versus amisulpride. Neuropsychopharmacology, 30:381-390.

2004

Bliesener, N; Yokusoglu, H; Quednow, B B; Klingmüller, D; Kühn, K U (2004). Usefulness of bromocriptine in the treatment of amisulpride-induced hyperprolactinemia. Pharmacopsychiatry 37:189-191.

Kühn, K U; Joe, A; Meyer, K; Reichmann, K; Maier, W; Rao, M L; Reinhardt, M J; Biersack, H J; Quednow, B B (2004). Neuroimaging and 5-HT2C-receptor-polymorphism: A HMPAO-SPECT-study in healthy male probands using m-CPP-challenge of the 5HT2C-receptor. Pharmacopsychiatry, 37:286-91.

Kühn, K U; Quednow, B B; Landen, H; Riedel, M; Thiel, M (2004). Lebensqualität und Therapieerfolg in der ambulanten Schizophrenie-Therapie mit Flupentixol: Eine Anwendungsbeobachtung. Fortschritte der Neurologie-Psychiatrie, 72:397-403.

Quednow, B B; Kühn, K U; Hoenig, K; Maier, W; Wagner, M (2004). Effects of serotonergic and noradrenergic antidepressants on auditory startle response in patients with Major Depression. Psychopharmacology, 175:399-406.

Quednow, B B; Kühn, K U; Hoenig, K; Maier, W; Wagner, M (2004). Prepulse inhibition and habituation of acoustic startle response in male MDMA (‘Ecstasy‘) users, cannabis users, and healthy controls. Neuropsychopharmacology, 29:982-90.

Before 2004

Kühn, K U; Quednow, B B; Thiel, M; Falkai, P; Maier, W; Elger, C E (2003). Antidepressive treatment in patients with temporal lobe epilepsy and major depression: A prospective study with 3 different antidepressants. Epilepsy & Behavior, 4:674-679.

Kühn, K U; Quednow, B B; Bagli, M; Meyer, M; Feuchtl, A; Westheide, J; Frahnert, C; Maier, W; Rao, M L (2002). Allelic variants of the serotonin-2C receptor and neuroendocrinological responses to the serotonin2C receptor. Pharmacopsychiatry, 35:226-230.

Kühn, K U; Quednow, B B; Barkow, C; Heun, R; Linden, M; Maier, W (2002). Psychosoziale Beeinträchtigung bei Patienten mit depressiven Störungen in der Allgemeinarztpraxis. Der Nervenarzt, 73:644-650.